Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 12;14(4):641-648.
doi: 10.1016/j.dsx.2020.05.018. Online ahead of print.

Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-Clinical and Clinical Studies

Affiliations
Free PMC article

Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-Clinical and Clinical Studies

Awadhesh Kumar Singh et al. Diabetes Metab Syndr. .
Free PMC article

Abstract

Background & aims: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19.

Methods: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as "Remdesivir" or 'GS-5734″ AND "COVID-19" or "SARS-CoV-2" and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19.

Results: Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality.

Conclusions: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.

Keywords: COVID-19; Clinical outcome; Mortality; Remdesivir; SARS-Co-V-2.

Conflict of interest statement

Declaration of competing interest Nothing to declare by all the authors.

Similar articles

See all similar articles

References

    1. Lo M.K., Jordan R., Arvey A. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep. 2017;7:43395. - PMC - PubMed
    1. Sheahan T.P., Sims A.C., Graham R.L. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9
    1. Agostini M.L., Andres E.L., Sims A.C., Graham R.L., Sheahan T.P., Lu X. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9 doi: 10.1128/mBio.00221-18. - DOI
    1. Summary on compassionate use remdesivir Gilead. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf (Accessed May 5, 2020)
    1. Mulangu S., Dodd L.E., Davey R.T., Jr. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303. - PubMed
Feedback